22nd Century to Make Proprietary Research Cigarettes Available Worldwide to Scientists, Researchers, and Governments
May 19 2016 - 10:29AM
Business Wire
22nd Century Group, Inc. (NYSE MKT:XXII), a plant
biotechnology company that is a leader in tobacco harm reduction,
announced today that the Company has launched a new line of
Research Cigarettes with varying levels of nicotine. Similar to the
Company’s SPECTRUM® brand research cigarettes that are sold only to
the National Institute on Drug Abuse (NIDA), 22nd Century’s new
proprietary Research Cigarettes are available directly to
accredited scientists, researchers, universities and governments –
worldwide. 22nd Century is the only company in the world capable of
producing tobacco research cigarettes with varying levels of
nicotine that range from 95% less nicotine than conventional
cigarettes (0.5mg/g) to 2X - 3X the nicotine content of
conventional cigarettes (50mg/g).
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160519006042/en/
22nd Century's new research cigarettes
are available in any configuration and in any style requested by
researchers. (Graphic: Business Wire)
“At the Society for Research on Nicotine (SRNT) Annual Meeting
held in Chicago in March of this year, the Company received
numerous requests for variable nicotine-level research cigarettes
from domestic and international scientists wishing to conduct
nicotine addictive threshold and smoking cessation studies. 22nd
Century is eager to provide scientists all over the world with the
means to conduct their important smoking research,” explained Dr.
Paul Rushton, Vice President of Plant Biotechnology at 22nd Century
Group.
22nd Century custom designs and produces research cigarettes
with precise tobacco blends, nicotine contents, filtration, tar
yields, and even custom taste characteristics for each clinical
study according to the exact specifications required by scientific
researchers. With an approved blend and packaging design, 22nd
Century can design, produce and ship research cigarettes in a
matter of weeks, thus speeding up the often lengthy and cumbersome
process researchers currently endure in order to study behaviors
and health risks associated with the use of tobacco products.
In addition to the significant revenue potential of this
initiative, the Company anticipates that the research generated
through the use of 22nd Century’s Very Low Nicotine research
cigarettes will add to the growing number of peer-reviewed
scientific studies that demonstrate the public health benefits of
22nd Century’s proprietary tobaccos. Such independent studies
formed the backbone of 22nd Century’s December 2015 Modified Risk
Tobacco Product (MRTP) application to the U.S. Food and Drug
Administration (FDA). Indeed, many such scientific studies
employing the Company’s research cigarettes with varying levels of
nicotine are funded by the FDA itself, including the landmark Eric
C. Donny, Ph.D. et al. clinical study that was published in the
October 2015 issue of The New England Journal of Medicine (N Engl J
Med 2015; 373:1340-1349). The FDA is also currently funding –
at a cost estimated to exceed $20 million – a follow-up clinical
study seeking the best method to quit smoking: an immediate
reduction in nicotine to non-addictive levels versus a gradual
reduction in nicotine (ClinicalTrials.gov NCT02139930). No matter
which protocol proves most effective, 22nd Century is the only
company in the world capable of producing the critical final
product: combustible tobacco cigarettes with non-addictive levels
of nicotine.
“Without 22nd Century’s unique ability to provide research
cigarettes with varying nicotine levels, many important research
projects would simply be impossible to conduct,” explained Henry
Sicignano III, the Company’s President and Chief Executive Officer.
“Accordingly, due to the increasing demand for our SPECTRUM®
research cigarettes, we felt compelled to make similar research
cigarettes available directly to scientists around the globe.
What’s more, unlike SPECTRUM® cigarettes, 22nd Century’s new
research cigarettes will be available in any configuration and in
any style requested by researchers. We expect this new product line
to grow rapidly.”
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on
technology which allows it to increase or decrease the level of
nicotine in tobacco plants and the level of cannabinoids in
cannabis plants through genetic engineering and plant breeding. The
Company’s primary mission is to reduce the harm caused by smoking.
22nd Century currently owns or exclusively controls more than 200
issued patents and more than 50 pending patent applications around
the world. Visit www.xxiicentury.com for more information.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release, including but not limited to our future revenue
expectations. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2015, filed on February 18, 2016,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S. Securities and Exchange Commission
which attempt to advise interested parties of the risks and factors
that may affect our business, financial condition, results of
operation and cash flows. If one or more of these risks or
uncertainties materialize, or if the underlying assumptions prove
incorrect, our actual results may vary materially from those
expected or projected.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160519006042/en/
Investor Relations:IRTH CommunicationsAndrew Haag,
866-976-4784xxii@irthcommunications.comorRedington, Inc.Tom
Redington, 203-222-7399
22nd Century (AMEX:XXII)
Historical Stock Chart
From Mar 2024 to Apr 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From Apr 2023 to Apr 2024